Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients

Makoto Shimizu, Masashi Kondo, Yasushi Ito, Hiroaki Kume, Ryujiro Suzuki, Kenichi Yamaki

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The Fas/Fas ligand (FasL) system is a major regulator of apoptosis. Chemotherapeutic drugs have been shown to induce Fas expression on the surface of lung cancer cells, and cancer cell apoptosis. However, this mechanism is not considered to be associated with Fas expressed on lung cancer cells. Soluble Fas and FasL concentrations are reportedly elevated in the peripheral blood of patients with lung cancer, but the roles of circulating soluble Fas and FasL in that disease have not been clarified. Materials and methods: We measured the circulating soluble Fas and FasL levels in 21 patients with small cell lung cancer (SCLC), and 12 healthy matched controls, in order to examine whether such ligands could provide any important information and/or reveal any new clinical features of SCLC. Results: In the CR patients, the neuronal specific enolase (NSE), soluble Fas and soluble FasL concentrations were 21.26 ± 3.65 ng/ml, 3.58 ± 0.19 ng/ml and 0.50 ± 0.15 ng/ml, while in the partial response (PR)/no change (NC)/progressive disease (PD) group of patients they were 33.96 ± 7.86 ng/ml, 5.29 ± 0.29 ng/ml and 0.59 ± 0.07 ng/ml, respectively. The NSE, soluble Fas and soluble FasL concentrations were all elevated in the PR/NC/PD patients, however, significant differences were only seen in Fas concentration between CR and PR/NC/PD patients and CR patients and the controls (p < 0.001). Conclusions: Serum soluble Fas and FasL play important roles in the proliferation and metastasis of SCLC, as well as in the cytotoxic reaction and apoptosis induced by anticancer drugs in SCLC. Further study of the mechanisms and participation of circulating soluble Fas and FasL is necessary to develop treatment strategies for SCLC.

Original languageEnglish
Pages (from-to)175-180
Number of pages6
JournalCancer Detection and Prevention
Volume29
Issue number2
DOIs
Publication statusPublished - 25-04-2005

Fingerprint

Fas Ligand Protein
Small Cell Lung Carcinoma
Neoplasm Metastasis
Drug Therapy
Lung Neoplasms
Phosphopyruvate Hydratase
Apoptosis
Pharmaceutical Preparations
Ligands
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shimizu, Makoto ; Kondo, Masashi ; Ito, Yasushi ; Kume, Hiroaki ; Suzuki, Ryujiro ; Yamaki, Kenichi. / Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. In: Cancer Detection and Prevention. 2005 ; Vol. 29, No. 2. pp. 175-180.
@article{708e077c332f4ee79e824de3bb4e0f96,
title = "Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients",
abstract = "Background: The Fas/Fas ligand (FasL) system is a major regulator of apoptosis. Chemotherapeutic drugs have been shown to induce Fas expression on the surface of lung cancer cells, and cancer cell apoptosis. However, this mechanism is not considered to be associated with Fas expressed on lung cancer cells. Soluble Fas and FasL concentrations are reportedly elevated in the peripheral blood of patients with lung cancer, but the roles of circulating soluble Fas and FasL in that disease have not been clarified. Materials and methods: We measured the circulating soluble Fas and FasL levels in 21 patients with small cell lung cancer (SCLC), and 12 healthy matched controls, in order to examine whether such ligands could provide any important information and/or reveal any new clinical features of SCLC. Results: In the CR patients, the neuronal specific enolase (NSE), soluble Fas and soluble FasL concentrations were 21.26 ± 3.65 ng/ml, 3.58 ± 0.19 ng/ml and 0.50 ± 0.15 ng/ml, while in the partial response (PR)/no change (NC)/progressive disease (PD) group of patients they were 33.96 ± 7.86 ng/ml, 5.29 ± 0.29 ng/ml and 0.59 ± 0.07 ng/ml, respectively. The NSE, soluble Fas and soluble FasL concentrations were all elevated in the PR/NC/PD patients, however, significant differences were only seen in Fas concentration between CR and PR/NC/PD patients and CR patients and the controls (p < 0.001). Conclusions: Serum soluble Fas and FasL play important roles in the proliferation and metastasis of SCLC, as well as in the cytotoxic reaction and apoptosis induced by anticancer drugs in SCLC. Further study of the mechanisms and participation of circulating soluble Fas and FasL is necessary to develop treatment strategies for SCLC.",
author = "Makoto Shimizu and Masashi Kondo and Yasushi Ito and Hiroaki Kume and Ryujiro Suzuki and Kenichi Yamaki",
year = "2005",
month = "4",
day = "25",
doi = "10.1016/j.cdp.2004.09.001",
language = "English",
volume = "29",
pages = "175--180",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "2",

}

Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. / Shimizu, Makoto; Kondo, Masashi; Ito, Yasushi; Kume, Hiroaki; Suzuki, Ryujiro; Yamaki, Kenichi.

In: Cancer Detection and Prevention, Vol. 29, No. 2, 25.04.2005, p. 175-180.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients

AU - Shimizu, Makoto

AU - Kondo, Masashi

AU - Ito, Yasushi

AU - Kume, Hiroaki

AU - Suzuki, Ryujiro

AU - Yamaki, Kenichi

PY - 2005/4/25

Y1 - 2005/4/25

N2 - Background: The Fas/Fas ligand (FasL) system is a major regulator of apoptosis. Chemotherapeutic drugs have been shown to induce Fas expression on the surface of lung cancer cells, and cancer cell apoptosis. However, this mechanism is not considered to be associated with Fas expressed on lung cancer cells. Soluble Fas and FasL concentrations are reportedly elevated in the peripheral blood of patients with lung cancer, but the roles of circulating soluble Fas and FasL in that disease have not been clarified. Materials and methods: We measured the circulating soluble Fas and FasL levels in 21 patients with small cell lung cancer (SCLC), and 12 healthy matched controls, in order to examine whether such ligands could provide any important information and/or reveal any new clinical features of SCLC. Results: In the CR patients, the neuronal specific enolase (NSE), soluble Fas and soluble FasL concentrations were 21.26 ± 3.65 ng/ml, 3.58 ± 0.19 ng/ml and 0.50 ± 0.15 ng/ml, while in the partial response (PR)/no change (NC)/progressive disease (PD) group of patients they were 33.96 ± 7.86 ng/ml, 5.29 ± 0.29 ng/ml and 0.59 ± 0.07 ng/ml, respectively. The NSE, soluble Fas and soluble FasL concentrations were all elevated in the PR/NC/PD patients, however, significant differences were only seen in Fas concentration between CR and PR/NC/PD patients and CR patients and the controls (p < 0.001). Conclusions: Serum soluble Fas and FasL play important roles in the proliferation and metastasis of SCLC, as well as in the cytotoxic reaction and apoptosis induced by anticancer drugs in SCLC. Further study of the mechanisms and participation of circulating soluble Fas and FasL is necessary to develop treatment strategies for SCLC.

AB - Background: The Fas/Fas ligand (FasL) system is a major regulator of apoptosis. Chemotherapeutic drugs have been shown to induce Fas expression on the surface of lung cancer cells, and cancer cell apoptosis. However, this mechanism is not considered to be associated with Fas expressed on lung cancer cells. Soluble Fas and FasL concentrations are reportedly elevated in the peripheral blood of patients with lung cancer, but the roles of circulating soluble Fas and FasL in that disease have not been clarified. Materials and methods: We measured the circulating soluble Fas and FasL levels in 21 patients with small cell lung cancer (SCLC), and 12 healthy matched controls, in order to examine whether such ligands could provide any important information and/or reveal any new clinical features of SCLC. Results: In the CR patients, the neuronal specific enolase (NSE), soluble Fas and soluble FasL concentrations were 21.26 ± 3.65 ng/ml, 3.58 ± 0.19 ng/ml and 0.50 ± 0.15 ng/ml, while in the partial response (PR)/no change (NC)/progressive disease (PD) group of patients they were 33.96 ± 7.86 ng/ml, 5.29 ± 0.29 ng/ml and 0.59 ± 0.07 ng/ml, respectively. The NSE, soluble Fas and soluble FasL concentrations were all elevated in the PR/NC/PD patients, however, significant differences were only seen in Fas concentration between CR and PR/NC/PD patients and CR patients and the controls (p < 0.001). Conclusions: Serum soluble Fas and FasL play important roles in the proliferation and metastasis of SCLC, as well as in the cytotoxic reaction and apoptosis induced by anticancer drugs in SCLC. Further study of the mechanisms and participation of circulating soluble Fas and FasL is necessary to develop treatment strategies for SCLC.

UR - http://www.scopus.com/inward/record.url?scp=17044410106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044410106&partnerID=8YFLogxK

U2 - 10.1016/j.cdp.2004.09.001

DO - 10.1016/j.cdp.2004.09.001

M3 - Article

C2 - 15829378

AN - SCOPUS:17044410106

VL - 29

SP - 175

EP - 180

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 2

ER -